Home/Pipeline/Novel Small Molecule LAG-3 Antagonist

Novel Small Molecule LAG-3 Antagonist

Oncology

ResearchEarly-stage

Key Facts

Indication

Oncology

Phase

Research

Status

Early-stage

Company

Immutep

About Immutep

Immutep is a global leader in the development of immunotherapies targeting the LAG-3 immune checkpoint, with a mission to deliver safe and effective treatments for cancer and autoimmune diseases. The company's strategy is built on a multi-modal LAG-3 platform, featuring its lead clinical asset eftilagimod alfa (efti), a first-in-class MHC Class II agonist, and several other clinical-stage candidates. With strategic partnerships with major pharmaceutical companies and a pipeline advancing in key oncology indications, Immutep is positioned to capitalize on the growing immuno-oncology market.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active